Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma

被引：2

作者：

Wada-Shimosato, Yuko ^{[1
]}

Ikeda, Junji ^{[1
]}

Tsujimoto, Shin-ichi ^{[1
]}

Sasaki, Koji ^{[1
]}

Yanagimachi, Masakatsu ^{[1
]}

Kajiwara, Ryosuke ^{[1
]}

Shiba, Norio ^{[1
]}

Murata, Hidetoshi ^{[2
]}

Kawahara, Nobutaka ^{[2
]}

Yamanaka, Shoji ^{[3
]}

Tanoshima, Reo ^{[1
]}

Ito, Shuichi ^{[1
]}

机构：

[1] Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa, Japan

[2] Yokohama City Univ, Sch Med, Dept Neurosurg, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2019年 / 41卷 / 07期

基金：

日本学术振兴会;

关键词：

primary central nervous system lymphoma; intraventricular rituximab; non-Hodgkin lymphoma; CD20; MANAGEMENT; RADIATION; CHILDREN; THERAPY; TRIAL; BRAIN;

D O I：

10.1097/MPH.0000000000001291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of extranodal non-Hodgkin lymphoma that carries an unsatisfactory prognosis. Treating refractory PCNSL is challenging because of resistance to conventional cytotoxic and intrathecal chemotherapies. Therefore, novel therapeutic approaches are needed. Here, we report a 12-year-old boy with CD20-positive PCNSL, which was refractory to combination chemotherapy and intravenous rituximab. However, the patient achieved complete remission after repeated intraventricular rituximab administration. The results of this case indicate that intraventricular rituximab is an effective option to treat refractory PCNSL in children.

引用

页码：571 / 573

页数：3

共 50 条

[1] Intrathecal rituximab in complex treatment of refractory CD20-positive primary CNS lymphoma
Savic, I.
Urosevic, I.
Popovic, S.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 436 - 436
[2] INTRAVENOUS RITUXIMAB COMBINED WITH TEMOZOLOMIDE AS A SECOND-LINE THERAPY FOR CD20-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA
Matsuno, Akira
Murakami, Mineko
Nakaguchi, Hiroshi
Sasaki, Mitsuyoshi
Uno, Takeshi
Ide, Fuyuaki
Tanaka, Hideki
Fujimaki, Takamitsu
[J]. NEURO-ONCOLOGY, 2009, 11 (06) : 970 - 970
[3] Central nervous system involvement in CD20-positive primary peripheral T-cell lymphoma, not otherwise specified
Katayama, Y.
Saitou, K.
Yokote, H.
Toru, S.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 388 - 389
[4] Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab
Schulz, H
Pels, H
Schmidt-Wolf, I
Zeelen, U
Germing, U
Engert, A
[J]. HAEMATOLOGICA, 2004, 89 (06) : 753 - 754
[5] Intraperitoneal and intrapleural application of Rituximab in refractory CD20-positive B-cell lymphoma
Christoph, S.
Sellmann, L.
Roeth, A.
Elmaagacli, A. H.
Beelen, D. W.
Duehrsen, U.
[J]. ONKOLOGIE, 2010, 33 : 253 - 253
[6] Intraventricular treatment of relapsed and refractory central nervous system (CNS) lymphoma with rituximab.
Schulz, H
Pels, H
Hom, E
Thall, A
Engert, A
[J]. BLOOD, 2001, 98 (11) : 249B - 249B
[7] Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
Batchelor, T. T.
Lesser, G. J.
Grossman, S. A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[8] Intraventricular primary central nervous system lymphoma
Guedes, LC
Barroso, C
Ruivo, N
Pimentel, JG
[J]. JOURNAL OF NEUROLOGY, 2005, 252 : 68 - 68
[9] CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab
Yan, Min
Dong, Zhaoming
Zhao, Frank
Chauncey, Thomas
Deauna-Limayo, Delva
Wang-Rodriguez, Jessica
Liu, Dayu
Wang, Huan-You
Pilz, Renate
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (01) : 77 - 80
[10] A Case of Intraventricular Primary Central Nervous System Lymphoma
Funaro, Kimberly
Bailey, Katie C.
Aguila, Sadie
Agosti, Steven J.
Vaillancourt, Christopher
[J]. JOURNAL OF RADIOLOGY CASE REPORTS, 2014, 8 (03): : 1 - 8

← 1 2 3 4 5 →